Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 5Phase NA 3Phase EARLY_PHASE1 2Phase 3 2Phase 1/2 2

Status

Completed 529Unknown 238Recruiting 159Terminated 157Active not recruiting 75Withdrawn 63Not yet recruiting 62Suspended 6Enrolling by invitation 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 1

Conditions

Colorectal Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Glioma 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peritoneal Neoplasms 2Osteosarcoma 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Diffuse Intrinsic Pontine Glioma 2Warts 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

regorafenib 1Riluzole 1Radiosurgery 1Maintenance 1Hepatectomy 1Flavonoids 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Colorectal Neoplasms × Clear all
NCT03722680 2026-05-20

RILUZOX-01

UNICANCER

Phase 2 Suspended
80 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07071961 2026-02-17

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

M.D. Anderson Cancer Center

Phase 2 Suspended
16 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05375708 2025-03-28

SIRIUS

UMC Utrecht

Phase 2 Suspended
93 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04840186 2024-11-12

EXCALIBUR3

Oslo University Hospital

Phase 2 Suspended
62 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01723306 2016-06-14

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Roger Williams Medical Center

Phase 2 Suspended
48 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00609310 2012-02-03

Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence

Technische Universität Dresden

Phase 2 Suspended
382 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡